Keppra (levetiracetam) is not a mood stabilizer. It is an anticonvulsant approved by the FDA solely for treating seizures, and it has no approved psychiatric indication. While some other anti-seizure medications like lamotrigine have crossed over into psychiatry as legitimate mood stabilizers, Keppra has not made that jump, and the clinical evidence suggests it probably shouldn’t.
Why Keppra Gets Confused With Mood Stabilizers
The confusion is understandable. Several anticonvulsants do double duty as mood stabilizers. Lamotrigine, for example, is FDA-approved both for seizures and for stabilizing mood in bipolar I disorder. Valproate is another anticonvulsant widely used in bipolar treatment. Because these drugs share a category with Keppra, it’s natural to assume Keppra might work similarly. It doesn’t. Different anticonvulsants affect the brain through different mechanisms, and the properties that make one useful for mood regulation don’t automatically apply to another in the same drug class.
What the Clinical Trials Actually Show
The strongest test of Keppra’s potential as a mood treatment came from a randomized, double-blind, placebo-controlled trial in patients with bipolar depression. Researchers gave participants either Keppra (up to 2,500 mg per day) or a placebo for six weeks alongside their existing medications. The result: Keppra performed no better than placebo on any measure of depression severity. There was no significant difference in depression scores, anxiety scores, or overall clinical improvement.
The remission rates were particularly telling. Zero patients in the Keppra group achieved remission, compared to 23% in the placebo group. That’s not just a failure to help; the placebo group actually did statistically better. The study’s conclusion was blunt: levetiracetam was not superior to placebo for treating bipolar depression.
Some earlier, smaller studies painted a more optimistic picture. Open-label reports (where both the patient and doctor know what’s being given) suggested possible benefits for acute mania, social anxiety, and panic disorder. One uncontrolled study in epilepsy patients found improvements in depression and anxiety after three months of Keppra treatment. But open-label and uncontrolled studies are notoriously unreliable for psychiatric conditions, where the placebo effect is strong. When Keppra was put through a rigorous controlled trial, the benefits disappeared.
Keppra’s Effect on Mood Is Often Negative
Rather than stabilizing mood, Keppra is more likely to destabilize it. The drug carries well-documented psychiatric side effects that are sometimes called “Keppra rage” by patients and caregivers. In clinical studies, roughly 10% of patients develop irritability, about 2.5% experience anger, and 2.6% become aggressive. These effects are significant enough that 2 to 3% of patients discontinue the medication because of them.
Children and adolescents are hit harder. Psychiatric and behavioral side effects occur in 12 to 38.7% of pediatric patients, and about 16% stop taking the drug because of these problems.
The FDA requires that Keppra’s label warn about behavioral abnormalities and psychotic symptoms. The label also carries the class-wide warning that applies to all anti-seizure drugs: patients taking them have roughly twice the risk of suicidal thoughts or behavior compared to those on placebo. That translates to about 1 in 530 treated patients developing suicidal thinking or behavior, and the risk can appear within the first week of treatment.
Who Is Most at Risk for Mood Problems on Keppra
People with a prior history of psychiatric conditions appear more vulnerable to Keppra’s mood-related side effects. This creates a particular concern for anyone considering the drug for mood purposes: the very population that might seek mood stabilization is the same population most likely to have a bad psychiatric reaction to it. If you’re taking Keppra for epilepsy and notice new irritability, depression, anxiety, or aggressive feelings, those are recognized side effects worth discussing with your prescriber, not signs that the drug is “working on your mood.”
How It Compares to Proven Mood Stabilizers
The anticonvulsants that genuinely work as mood stabilizers have undergone large-scale trials confirming their psychiatric benefits, earning them specific FDA approvals for bipolar disorder. Lamotrigine is approved for preventing mood episodes in bipolar I disorder. Valproate is approved for acute mania. Lithium, while not an anticonvulsant, remains the gold-standard mood stabilizer with decades of evidence.
Keppra has none of this. Its only FDA-approved use is for partial-onset seizures (in the extended-release form, for patients 12 and older). No major psychiatric organization recommends it for bipolar disorder or any other mood condition, and the best available controlled trial found it ineffective. Being an anticonvulsant is not, on its own, enough to make a drug a mood stabilizer.